ARS Pharmaceuticals (SPRY) opened FY 2025 with third quarter revenue of US$32.5 million and a basic EPS loss of US$0.52, alongside a net loss of US$51.2 million. This keeps the story firmly focused on the trade off between growth and profitability. The company has seen quarterly revenue move from US$7.97 million in Q1 2025 to US$15.7 million in Q2 2025 and then to US$32.5 million in Q3 2025. Basic EPS went from a loss of US$0.35 in Q1 to a loss of US$0.46 in Q2 and a loss of US$0.52 in Q3, setting up a results season where investors are watching how fast margins can catch up to the top line.

With the headline numbers on the table, the next step is to see how this earnings print lines up against the dominant growth focused narrative around SPRY and where the latest margin trends might challenge those expectations.

US$80 million trailing loss keeps profitability in focus

• On a trailing 12 month basis to Q3 2025, ARS recorded a net loss of US$80.0 million on US$142.8 million of revenue, compared with a single quarter net loss of US$51.2 million on US$32.5 million of revenue in Q3 2025, so the quarterly loss now makes up a large share of the recent 12 month loss.
• Bears highlight that losses have expanded at about 19.9% per year over the past five years, and the Q3 2025 net loss of US$51.2 million alongside SG&A of US$54.3 million fits that concern that heavy selling spend could keep pressure on margins if revenue from neffy does not keep pace with these operating costs.
  • The trailing 12 month net loss of US$80.0 million follows a period that included a profitable Q4 2024 with net income of US$49.9 million, so the recent quarterly losses are weighing against that earlier profitable period.
  • Given ARS is currently unprofitable on a trailing 12 month basis, the bearish view that the company may struggle to reach and sustain profitability if spending remains high finds support in these recent figures.

Over the last few quarters, ARS has been leaning hard into growth, and skeptics worry that this pattern of losses could persist even as sales build. 🐻 ARS Pharmaceuticals Bear Case

Revenue climbs to US$32.5 million while losses widen

• Quarterly revenue stepped up from US$7.97 million in Q1 2025 to US$15.7 million in Q2 2025 and then to US$32.5 million in Q3 2025, while quarterly net losses went from US$33.9 million to US$44.9 million and then to US$51.2 million over the same stretch, so higher sales are currently arriving alongside larger losses.
• Supporters of the bullish narrative point out that analysts forecast revenue growth of 32.6% per year and earnings growth of 72.42% per year with an expectation that ARS becomes profitable within three years, and they see the rapid move from US$7.97 million to US$32.5 million in quarterly revenue as early evidence that neffy driven growth can eventually absorb current operating costs.
  • Trailing 12 month revenue of US$142.8 million compares with US$89.1 million at the end of Q4 2024, which bulls view alongside forecasts of strong revenue growth and margin improvement as a sign that scale is building off the initial launch phase.
  • Because these growth forecasts sit against a history of widening losses, the bullish case leans heavily on the idea that future operating leverage will eventually turn that revenue base into positive earnings.

If you are trying to weigh that growth story against the current losses, it can help to see how bullish investors connect these numbers to their long term thesis. 🐂 ARS Pharmaceuticals Bull Case

P/S of 6.3x and DCF fair value flag a valuation gap

• With a current share price of US$9.05, ARS trades on a P/S of 6.3x versus a peer average of 9.5x and a US Biotechs industry average of 12x, and it also sits well below an indicated DCF fair value of US$94.44, which together point to a wide gap between recent trading levels and these valuation metrics.
• Consensus narrative notes that forecasts for 32.6% annual revenue growth and 72.42% annual earnings growth, plus an analyst price target of US$28.83, are central to why some investors see the current 6.3x P/S and discount to DCF fair value as attractive, while the trailing 12 month loss of US$80.0 million and five year loss expansion of 19.9% keep others focused on the execution risk behind those forecasts.
  • The expectation that ARS could become profitable within three years is a key part of why valuation metrics derived from growth models look generous compared with the current share price.
  • At the same time, the present unprofitable status and recent quarterly loss of US$51.2 million show that these

    Next Steps

    To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for ARS Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

    If this mix of optimism and concern has you on the fence, take a moment to review the numbers yourself and act while the data is fresh. Our work also highlights that the company has rewards the market is watching. It can be useful to see those laid out in one place through 3 key rewards.

    Explore Alternatives

    SPRY is growing revenue but still carries sizeable losses, with heavy SG&A spending and an unprofitable trailing 12 month record. This keeps risk front and center for investors to evaluate.

    If that level of uncertainty feels uncomfortable, shift your research toward businesses screened for financial resilience by checking out 64 resilient stocks with low risk scores that aim to keep downside in check.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.